Monotherapy or in combination w/ dabrafenib for unresectable or metastatic melanoma w/ a BRAF V600 mutation. In combination w/ tafinlar for adjuvant treatment of stage III melanoma w/ BRAF V600E or V600K mutation & involvement of lymph node(s). In combination w/ dabrafenib for advanced NSCLC w/ a BRAF V600 mutation.
Evaluate LVEF in all patients prior to initiation of treatment w/ periodic follow-up w/in 8 wk of initiating therapy, then continue during treatment; patients w/ conditions that may impair LVEF. Haemorrhage may occur. Disorders associated w/ visual disturbances, including chorioretinopathy or retinal pigment epithelial detachment & retinal vein occlusion (RVO). Not recommended in patients w/ history of retinal vein occlusion. Perform a thorough ophth evaluation at baseline & during treatment. Permanently discontinue if RVO occurs. Rash. DVT/pulmonary embolism. Increased incidence & severity of pyrexia. Monitor serum creatinine & other evidence of renal function during & following severe events of pyrexia. Patients w/ risk factors for GIT perforation, including history of diverticulitis & GIT metastases, & concomitant use w/ drugs w/ recognised risk of GI perforation. Severe renal, & moderate or severe hepatic impairment. Pregnancy & lactation.
Sign Out
